SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MJ who wrote (1107)10/11/1998 4:45:00 PM
From: nord   of 1510
 


Is it possible that the IMNR treatment for AIDS could be the opening of
the door for treating other viruses in a similar fashion. Or even a
bridge to treating other diseases whose end results are similar in
nature---i.e. the breakdown of the autoimmune system. If so, this stock
could be a winner on many levels.

A second question ---is AIDS a new disease of this late century or is it
a disease such as polio which according to a recent documentary is
thought to be centuries old and became prevalent in the early part of
this century and later in the 1950's in this country as we began to
improve sanitation.
the possibilities for the type of therapy being developed by imnr is well documented on the website pipeline and this is just the start. which of these will prove to effect the natural histrory of disease be they infectious or autoimmune or malignancy awaits results of further study
AIDS is clearly a new disease although the exact date it was first infecting persons in the US is still open to debate there is evidence that it may have begun here as early as the 50's. The transmission of HIV is not through fecal contamination and hence does not directly result from poor sanitation.
IMNR is a biopharmaceutical company developing immune-based therapies to
induce specific T cell response for the treatment of HIV, autoimmune
diseases and cancer. For the six months ended 6/98, revenues totalled
$11.7 million, up from $1 million. Net loss applicable to Common
decreased 63% to $6.6 million. Revenues reflect licensed research
revenues received from Agouron. Lower loss reflects the absence of
initial costs related to clinical trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News